Cryotherapy for chronic rhinitis (IPG771)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 September 2023
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Anaphylaxis: assessment and referral after emergency treatment (CG134)Product type:GuidanceProgramme:Clinical guidelineLast updated: 24 August 2020Published: 14 December 2011
Intranasal phototherapy for allergic rhinitis (IPG616)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 13 June 2018
ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)Product type:GuidanceProgramme:Diagnostics guidancePublished: 18 May 2016
Omalizumab for previously treated chronic spontaneous urticaria (TA339)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2015
Drug allergy: diagnosis and management (CG183)Product type:GuidanceProgramme:Clinical guidelinePublished: 3 September 2014
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
Food allergy in under 19s: assessment and diagnosis (CG116)Product type:GuidanceProgramme:Clinical guidelinePublished: 23 February 2011
Thora-3Di for assessing asthma in children (MIB122)Product type:AdviceProgramme:Medtech innovation briefingPublished: 2 October 2017
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 August 2014
Chronic urticaria: off-label doses of cetirizine (ESUOM31)Product type:AdviceProgramme:Evidence summaryPublished: 8 July 2014
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 February 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2025
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria TS ID 11832Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over TS ID 12082Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC